Gilead Sciences (GILD)
In a report issued on September 11, Cory Kasimov from J.P. Morgan maintained a Buy rating on Gilead Sciences. The company’s shares closed yesterday at $73.97.
According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 2.9% and a 40.7% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Global Blood Therapeutics, and Jounce Therapeutics Inc.
Gilead Sciences has an analyst consensus of Strong Buy, with a price target consensus of $89.44, which is a 20.9% upside from current levels. In a report released yesterday, Jefferies also reiterated a Buy rating on the stock with a $95 price target.
Vital Therapies (VTL)
BTIG analyst Sean Lavin maintained a Hold rating on Vital Therapies yesterday. The company’s shares closed yesterday at $0.45, close to its 52-week low of $0.40.
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 15.2% and a 63.4% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings Inc, Helius Medical Technologies, and Tactile Systems Technology.
Currently, the analyst consensus on Vital Therapies is a Hold with an average price target of $0.50, representing an 11.1% upside. In a report released yesterday, Raymond James also downgraded the stock to Hold.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.